Member access

4-Traders Homepage  >  Shares  >  OTC Bulletin Board  >  Advaxis, Inc.    ADXS   US0076241092

ADVAXIS, INC.

 (ADXS)

0
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsForum 
Latest news on ADVAXIS, INC.
05/06 ADVAXIS, INC.: Advaxis Announces Promotion of Dr. Robert Petit and Daniel J. O'..
05/06 ADVAXIS, INC.: Advaxis Announces 2013 Annual Meeting of Stockholders
04/29 ADVAXIS, INC.: Advaxis Reports Encouraging Preliminary Data from Penn Phase 1 A..
04/22 ADVAXIS, INC.: Advaxis and FusionVax Sign a Memorandum of Understanding for the..
04/22 ADVAXIS, INC.: Advaxis Announces First Patient Dosed in Brown University Sponso..
04/18 ADVAXIS, INC.: Advaxis to Present at the BIO International Convention
04/17 ADVAXIS, INC.: Advaxis to Report 12-Month Survival from Its Phase 2 Study of AD..
03/26 ADVAXIS, INC.: Advaxis Announces Abstract Accepted for Oral Presentation at SIT..
03/13 ADVAXIS, INC.: Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th An..
03/11 ADVAXIS, INC.: University of Pennsylvania Researchers Receive Penn One Health A..
03/06 ADVAXIS, INC.: Advaxis Provides Business Outlook for 2013
02/28 ADVAXIS, INC.: Advaxis to Provide 2013 Business Outlook on March 6, 2013
02/19 ADVAXIS, INC.: Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Con..
02/07 ADVAXIS, INC.: Advaxis to Present at the 15th Annual BIO CEO & Investor Confere..
01/07 ADVAXIS, INC.: Advaxis to Present at the 6th Annual OneMedForum
01/03 ADVAXIS, INC.: Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Ch..
2012 ADVAXIS, INC.: Advaxis Receives Preliminary Approval for Sale of Losses from St..
2012 ADVAXIS, INC.: Advaxis to Present at NYC MedTech Program
2012 ADVAXIS, INC.: Advaxis Announces $11.4 Million in Financial Commitments
2012 ADVAXIS, INC.: Advaxis Updates Phase 2 Cervical Cancer Trial Data
2012 ADVAXIS, INC.: Advaxis Will Present at Rodman & Renshaw Annual Healthcare Confe..
2012 ADVAXIS, INC.: Advaxis Announces Two Abstracts Accepted for Presentation at SIT..
2012 ADVAXIS, INC.: UPenn Doses First Two Dogs in ADXS-HER2 Canine Osteosarcoma Stud..
2012 ADVAXIS, INC.: Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NC..
2012 ADVAXIS, INC.: Advaxis to Present at the 2012 Southern California Investment Fo..
2012 ADVAXIS, INC.: Advaxis Announces 2012 Annual Meeting of Stockholders
2012 ADVAXIS, INC.: Advaxis to Present at the 2012 BIO International Convention
2012 ADVAXIS, INC.: Advaxis to Present at the Inaugural Marcum MicroCap Conference o..
2012 ADVAXIS, INC.: Advaxis ADXS-PSA Construct Causes Significant Tumor Regression i..
2012 ADVAXIS, INC.: Advaxis Completes Enrollment of Cohort 2 in Phase 2 CIN 2/3 Stud..
2012 ADVAXIS, INC.: Advaxis to Report Updated Safety, Tumor Response, and Survival D..
2012 ADVAXIS, INC.: Advaxis Completes Enrollment in Phase 2 Cervical Cancer Study
2012 ADVAXIS, INC.: Advaxis Retires $4.5 Million in Debt, Adds $1,240,000 in New Fin..
2012 ADVAXIS, INC.: Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinica..
2012 ADVAXIS, INC.: Advaxis Announces Abstracts Accepted for Poster Presentation at ..
2012 ADVAXIS, INC.: Advaxis Research Accepted for American Association of Immunologi..
2012 ADVAXIS, INC.: Advaxis to Speak at 2012 World Immunotherapy Online Symposium
2012 ADVAXIS, INC.: Advaxis Awarded Best Therapeutic Vaccine
2012 ADVAXIS, INC.: Advaxis Announces Presentations at World Vaccine Congress 2012
2012 ADVAXIS, INC.: Advaxis Announces Collaboration with the Karolinska Institutet
2012 ADVAXIS, INC.: Advaxis Announces Abstracts Accepted for Poster Presentation at ..
2012 ADVAXIS, INC.: Advaxis Continues Collaboration with Former NCI Vaccines Chief i..
2012 ADVAXIS, INC.: Advaxis Named to Shortlist for Vaccine Industry Excellence Award
2012 ADVAXIS, INC.: Advaxis to Present at the 6th Annual International BIO-Europe Sp..
2012 ADVAXIS, INC.: Advaxis Low Dose Cohort 1 Meets 50% Efficacy Target In CIN 2/3
2012 ADVAXIS, INC.: Advaxis to Present at the 14th Annual BIO CEO & Investor Confere..
2012 ADVAXIS, INC.: Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preli..
2012 ADVAXIS, INC.: REPEAT/Advaxis Reports Preliminary Safety and Survival Data from..
2012 ADVAXIS, INC.: Advaxis Reports Preliminary Safety and Survival Data from a Phas..
2012 ADVAXIS, INC.: Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-H..
2012 ADVAXIS, INC.: Advaxis to Present at 5th Annual OneMedForum San Francisco 2012
2011 ADVAXIS, INC.: Advaxis Receives Additional Financing
2011 ADVAXIS, INC.: Southern California Investment Forum Hosts an Investor Gathering..
2011 ADVAXIS, INC.: Advaxis Reports Preliminary Data from ADXS-HPV Phase 2 Trial in ..
2011 ADVAXIS, INC.: Advaxis Completes Pre-IND Meeting for ADXS-HER2
2011 ADVAXIS, INC.: Advaxis Licenses Novel Antigen for Severe Breast Cancer and Othe..
2011 ADVAXIS, INC.: Advaxis Licenses Novel Antigen for Severe Breast Cancer and Othe..
2011 ADVAXIS, INC.: Advaxis Receives Additional Financing
2011 ADVAXIS, INC.: Advaxis Announces Notice of Allowance of US Patent for ADXS-HPV ..
2011 ADVAXIS, INC.: Advaxis to Present at the 2011 10th Annual BIO Investor Forum on..
2011 ADVAXIS, INC.: Advaxis ADXS-HPV Project Selected as One of the Windhover and Ca..
2011 ADVAXIS, INC.: Advaxis ADXS-HPV Project Selected as One of the Windhover and Ca..
2011 ADVAXIS, INC.: Advaxis Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immun..
2011 ADVAXIS I: Advaxis Will Present at the Rodman & Renshaw 13th Annual Healthcare ..
2011 ADVAXIS I: Advaxis Announces 2011 Annual Meeting of Stockholders
2011 ADVAXIS I: Diana Moore Appointed as Director, Investor Relations & Business Dev..
2011 ADVAXIS I: Advaxis Completes Pre-IND Meeting for ADXS-PSA
2011 ADVAXIS I: Advaxis Immunotherapies Classified as Non-Pathogenic Materials by th..
2011 ADVAXIS I: Advaxis Revises Protocol for CIN Study
2011 ADVAXIS I: Dr. Ashok Amin Joins Advaxis as Vice President of Research and Devel..
2011 ADVAXIS I: Advaxis Completes Enrollment of Low Dose Cohort in CIN Study
2011 ADVAXIS I: UPenn Initiates Canine Osteosarcoma Study with Advaxis HER2
2011 ADVAXIS I: Advaxis Granted Pre-IND Meeting with the FDA for Advaxis-PSA Prostat..
2011 ADVAXIS I: Chris L. French Joins Advaxis as Executive Director of Medical Affai..
2011 ADVAXIS I: Advaxis Included in the Mentor Capital Cancer Immunotherapy Index
1  2Next
Advertisement
Chart
Duration : Period :
Advaxis, Inc. Technical Analysis Chart | ADXS | US0076241092 | 4-Traders
Income Statement Evolution
Advaxis, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.